对局部进展期结肠癌新辅助化疗FOxTROT Ⅲ期临床试验的评价  

Evaluation of FOxTROT phase III clinical trial of neoadjuvant chemotherapy for locally advanced colon cancer

作　　者：薛栋 孙祺 王光辉[1] XUE Dong;SUN Qi;WANG Guanghui(Department of General Surgery,the First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China)

机构地区：[1]西安交通大学第一附属医院普通外科,陕西西安710061

出　　处：《现代肿瘤医学》2024年第3期558-560,共3页Journal of Modern Oncology

基　　金：国家自然科学基金项目(编号:81803026)。

摘　　要：目前,在局部进展期结肠癌新辅助化疗方面仍处于空白。FOxTROT研究是首个评估局部进展期结肠癌新辅助化疗策略的Ⅲ期试验,填补了该领域的空白。FOxTROT研究结果表明,术前6周的新辅助化疗具有合理性,显著降低了组织病理学分期、提高了R0切除率、降低了结肠癌术后2年复发率。由于FOxTROT研究存在局限性,还不能代表局部进展期结肠癌新辅助化疗的新标准,而应该是一种选择。At present,there is still a blank in neoadjuvant chemotherapy for locally advanced colon cancer.FOxTROT is the first phase III trial to evaluate the effectiveness of neoadjuvant chemotherapy strategy for locally advanced colon cancer,which fills the blank in this field.The results of FOxTROT show that neoadjuvant chemotherapy for 6 weeks before operation is reasonable,which significantly reduces the histopathological staging,improves the resection rate of R0,and reduces the 2-year recurrence rate of colon cancer after operation.Because of the limitations of FOxTROT research,it cannot represent the new standard of neoadjuvant chemotherapy for locally advanced colon cancer,but anoption.

关 键 词：结肠癌 局部进展期 新辅助化疗 FOxTROT 

分 类 号：R735.35[医药卫生—肿瘤]